⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
prnewswire.com
BMY
MRK
REGN
EXEL
AZN
GSK
A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall
globenewswire.com
AMGN
BMY
EXEL
EXAS
GENK
GSK
JNJ
MRK
NTRA
PFE
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
businesswire.com
EXEL
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
prnewswire.com
MRK
EXEL
LLY
ONCY
GILD
Biogen Announces Board Chair Transition
globenewswire.com
BIIB
ARE
EXEL
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
businesswire.com
EXEL
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
globenewswire.com
ALGN
AZN
EXEL
VRTX
XNCR
Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market USA - English APAC - Traditional Chinese USA - English
prnewswire.com
AAPL
TSLA
XOM
MSFT
GOOGL
AMZN
NVDA
META
BRK.A
JPM
V
JNJ
PG
MA
HD
UNH
DIS
BAC
PFE
MRK
TMO
ABT
MDT
BMY
AMGN
GILD
AZN
LLY
BIIB
REGN
VRTX
ALGN
ISRG
TDOC
EXAS
ZLAB
SCHR
APT
BILI
HSAI
UBOT
TIGR
INSM
YXT
CCEL
IMUX
INCY
CRSP
EDIT
NTLA
SRPT
EXEL
LULU
CROX
NKE
CPRI
PVH
RL
URBN
M
KSS
TJX
BBY
ROST
DLTR
WMT
TGT
COST
SBUX
MCD
CMG
YUM
QSR
CBRL
TXRH
NDSN
TTWO
EA
NTDOY
SONY
MSGS
AMC
IMAX
RCL
CCL
NCLH
AAL
DAL
UAL
LUV
ALK
JBLU
SKX
ADBE
CRM
INTC
AMD
QCOM
AMAT
MU
NXPI
SNPS
CDNS
ASML
PAYX
ADP
NOW
CSCO
ORCL
IBM
HPQ
DELL
ACN
INFY
SAP
ERIC
NOK
STM
UL
PEP
KO
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
businesswire.com
EXEL
EXEL Industries: Q1 2025–2026 revenue -17.5%
globenewswire.com
EXEL